drug
belantamab mafodotin
Marketedupdated 3mo agoby GlaxoSmithKline LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3all catalysts(1)
Trials studying belantamab mafodotin
- phase2A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
- phase2Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
- phase2Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma
- phase2Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma.
- phase2A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
- phase1A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
- phase3All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
- phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
News(3)
- Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology pushBetter-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.biopharma_dive · 22d ago
- GSK lung cancer drug gets speedy approval following $10.6B dealThe clearance is GSK’s first for a lung cancer medicine and the latest step forward in a yearslong push by the British drugmaker into oncology.biopharma_dive · 29d ago
- GSK, Hansoh ADC extends survival in lung cancer studyGSK claimed the result was a first for an ADC aimed at the “B7-H3” protein, an increasingly popular target of late among cancer drugmakers.biopharma_dive · 1mo ago
Data sources
last refreshed 1m ago
Found something off?
comments(0)
5-min edit window · permanent after that